Trade Aldeyra Therapeutics, Inc. - ALDX CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026235% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.004012% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Aldeyra Therapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 2.83 |
Open* | 2.92 |
1-Year Change* | -55.01% |
Day's Range* | 2.92 - 3.33 |
52 wk Range | 1.42-11.97 |
Average Volume (10 days) | 1.41M |
Average Volume (3 months) | 54.08M |
Market Cap | 143.53M |
P/E Ratio | -100.00K |
Shares Outstanding | 58.82M |
Revenue | N/A |
EPS | -0.78 |
Dividend (Yield %) | N/A |
Beta | 1.30 |
Next Earnings Date | Mar 7, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 1, 2023 | 2.83 | 0.06 | 2.17% | 2.77 | 2.87 | 2.67 |
Nov 30, 2023 | 2.76 | 0.00 | 0.00% | 2.76 | 2.88 | 2.75 |
Nov 29, 2023 | 2.74 | 0.06 | 2.24% | 2.68 | 2.93 | 2.68 |
Nov 28, 2023 | 2.68 | 0.18 | 7.20% | 2.50 | 2.70 | 2.45 |
Nov 27, 2023 | 2.59 | 0.10 | 4.02% | 2.49 | 2.60 | 2.41 |
Nov 24, 2023 | 2.50 | -0.02 | -0.79% | 2.52 | 2.63 | 2.49 |
Nov 22, 2023 | 2.49 | 0.06 | 2.47% | 2.43 | 2.60 | 2.42 |
Nov 21, 2023 | 2.42 | -0.24 | -9.02% | 2.66 | 2.69 | 2.42 |
Nov 20, 2023 | 2.63 | -0.14 | -5.05% | 2.77 | 2.84 | 2.61 |
Nov 17, 2023 | 2.83 | 0.37 | 15.04% | 2.46 | 2.90 | 2.45 |
Nov 16, 2023 | 2.46 | -0.06 | -2.38% | 2.52 | 2.55 | 2.41 |
Nov 15, 2023 | 2.50 | -0.03 | -1.19% | 2.53 | 2.67 | 2.49 |
Nov 14, 2023 | 2.55 | 0.08 | 3.24% | 2.47 | 2.56 | 2.44 |
Nov 13, 2023 | 2.43 | 0.15 | 6.58% | 2.28 | 2.43 | 2.21 |
Nov 10, 2023 | 2.26 | -0.08 | -3.42% | 2.34 | 2.34 | 2.18 |
Nov 9, 2023 | 2.33 | -0.22 | -8.63% | 2.55 | 2.58 | 2.30 |
Nov 8, 2023 | 2.59 | -0.08 | -3.00% | 2.67 | 2.87 | 2.50 |
Nov 7, 2023 | 2.74 | 0.48 | 21.24% | 2.26 | 2.74 | 2.24 |
Nov 6, 2023 | 2.24 | 0.03 | 1.36% | 2.21 | 2.41 | 2.18 |
Nov 3, 2023 | 2.18 | 0.09 | 4.31% | 2.09 | 2.24 | 2.05 |
Aldeyra Therapeutics, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Thursday, March 7, 2024 | ||
Time (UTC) 13:30 | Country US
| Event Q4 2023 Aldeyra Therapeutics Inc Earnings Release Q4 2023 Aldeyra Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Revenue | |||||
Total Operating Expense | 62.68 | 56.2195 | 36.421 | 63.0743 | 39.6992 |
Selling/General/Admin. Expenses, Total | 15.3739 | 11.283 | 9.98545 | 12.1547 | 9.87614 |
Research & Development | 47.3061 | 44.9365 | 24.6813 | 44.3518 | 29.823 |
Operating Income | -62.68 | -56.2195 | -36.421 | -63.0743 | -39.6992 |
Interest Income (Expense), Net Non-Operating | 0.65535 | -1.55674 | -1.61198 | 0.9375 | 0.80591 |
Net Income Before Taxes | -62.0246 | -57.7763 | -38.033 | -62.1368 | -38.8932 |
Net Income After Taxes | -62.0246 | -57.7763 | -37.5537 | -60.8268 | -38.8932 |
Net Income Before Extra. Items | -62.0246 | -57.7763 | -37.5537 | -60.8268 | -38.8932 |
Net Income | -62.0246 | -57.7763 | -37.5537 | -60.8268 | -38.8932 |
Income Available to Common Excl. Extra. Items | -62.0246 | -57.7763 | -37.5537 | -60.8268 | -38.8932 |
Income Available to Common Incl. Extra. Items | -62.0246 | -57.7763 | -37.5537 | -60.8268 | -38.8932 |
Diluted Net Income | -62.0246 | -57.7763 | -37.5537 | -60.8268 | -38.8932 |
Diluted Weighted Average Shares | 58.4059 | 54.0421 | 33.966 | 27.1118 | 21.6856 |
Diluted EPS Excluding Extraordinary Items | -1.06196 | -1.0691 | -1.10563 | -2.24355 | -1.7935 |
Diluted Normalized EPS | -1.06196 | -1.0691 | -1.05398 | -2.00131 | -1.7935 |
Unusual Expense (Income) | 0 | 1.75427 | 6.56775 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 10.3427 | 16.8033 | 13.6968 | 14.7846 | 17.7149 |
Selling/General/Admin. Expenses, Total | 3.37975 | 5.56742 | 4.73532 | 3.24494 | 3.14428 |
Research & Development | 6.96291 | 11.2359 | 8.96147 | 11.5396 | 14.5707 |
Operating Income | -10.3427 | -16.8033 | -13.6968 | -14.7846 | -17.7149 |
Interest Income (Expense), Net Non-Operating | 1.35566 | 1.1876 | 0.79463 | 0.23132 | -0.06602 |
Net Income Before Taxes | -8.987 | -15.6157 | -12.9022 | -14.5532 | -17.781 |
Net Income After Taxes | -8.987 | -15.6157 | -12.9022 | -14.5532 | -17.781 |
Net Income Before Extra. Items | -8.987 | -15.6157 | -12.9022 | -14.5532 | -17.781 |
Net Income | -8.987 | -15.6157 | -12.9022 | -14.5532 | -17.781 |
Income Available to Common Excl. Extra. Items | -8.987 | -15.6157 | -12.9022 | -14.5532 | -17.781 |
Income Available to Common Incl. Extra. Items | -8.987 | -15.6157 | -12.9022 | -14.5532 | -17.781 |
Diluted Net Income | -8.987 | -15.6157 | -12.9022 | -14.5532 | -17.781 |
Diluted Weighted Average Shares | 58.7919 | 58.7916 | 58.5646 | 58.4579 | 58.3015 |
Diluted EPS Excluding Extraordinary Items | -0.15286 | -0.26561 | -0.22031 | -0.24895 | -0.30498 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.15286 | -0.26561 | -0.22031 | -0.24895 | -0.30498 |
Unusual Expense (Income) |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 181.023 | 232.753 | 83.0593 | 75.1688 | 94.7693 |
Cash and Short Term Investments | 174.301 | 229.791 | 77.8583 | 73.3644 | 93.5997 |
Cash & Equivalents | 9.26828 | 129.426 | 54.3634 | 29.0624 | 45.2303 |
Short Term Investments | 29.8815 | 0 | 28.9386 | 46.2422 | |
Prepaid Expenses | 6.72223 | 2.96178 | 5.20096 | 1.80445 | 1.16959 |
Total Assets | 181.292 | 233.137 | 83.3525 | 75.5183 | 95.0912 |
Property/Plant/Equipment, Total - Net | 0.26854 | 0.38435 | 0.29324 | 0.34946 | 0.23523 |
Other Long Term Assets, Total | 0 | 0.08664 | |||
Total Current Liabilities | 15.3605 | 11.7727 | 12.4095 | 12.9078 | 8.47318 |
Accounts Payable | 0.13363 | 1.0197 | 0.38164 | 0.8083 | 3.05168 |
Accrued Expenses | 14.3152 | 10.753 | 8.36808 | 12.0995 | 5.4215 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.91176 | 0 | 3.65978 | 0 | |
Total Liabilities | 30.2836 | 27.4016 | 23.844 | 27.436 | 8.47318 |
Total Long Term Debt | 14.9231 | 15.5037 | 11.4345 | 14.5282 | 0 |
Long Term Debt | 14.9231 | 15.5037 | 11.4345 | 14.5282 | 0 |
Total Equity | 151.008 | 205.736 | 59.5086 | 48.0823 | 86.618 |
Common Stock | 0.05856 | 0.05808 | 0.03867 | 0.02866 | 0.02624 |
Additional Paid-In Capital | 507.77 | 500.369 | 296.386 | 247.41 | 225.136 |
Retained Earnings (Accumulated Deficit) | -356.717 | -294.692 | -236.916 | -199.362 | -138.535 |
Other Equity, Total | -0.10394 | 0 | 0 | 0.00587 | -0.00922 |
Total Liabilities & Shareholders’ Equity | 181.292 | 233.137 | 83.3525 | 75.5183 | 95.0912 |
Total Common Shares Outstanding | 58.5601 | 58.0812 | 38.6675 | 28.6568 | 26.2444 |
Cash | 135.151 | 100.365 | 23.4949 | 15.3635 | 2.12718 |
Other Liabilities, Total | 0 | 0.12523 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 147.21 | 155.479 | 168.017 | 181.023 | 189.483 |
Cash and Short Term Investments | 143.335 | 151.676 | 165.028 | 174.301 | 185.329 |
Cash & Equivalents | 46.5314 | 40.1714 | 39.7152 | 9.26828 | 22.1109 |
Prepaid Expenses | 3.87513 | 3.80356 | 2.98912 | 6.72223 | 4.15372 |
Other Current Assets, Total | |||||
Total Assets | 147.282 | 155.616 | 168.219 | 181.292 | 189.692 |
Property/Plant/Equipment, Total - Net | 0.07223 | 0.13723 | 0.20157 | 0.26854 | 0.2086 |
Total Current Liabilities | 21.6173 | 15.6051 | 16.0079 | 15.3605 | 24.195 |
Accounts Payable | 0.24719 | 0.27082 | 0.42969 | 0.13363 | 1.30693 |
Accrued Expenses | 7.90902 | 9.43998 | 14.6239 | 14.3152 | 10.439 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 13.4611 | 5.89432 | 0.95433 | 0.91176 | 12.4491 |
Total Liabilities | 24.2745 | 25.7332 | 30.9756 | 30.2836 | 27.4981 |
Total Long Term Debt | 2.65719 | 10.128 | 14.9677 | 14.9231 | 3.30304 |
Long Term Debt | 2.65719 | 10.128 | 14.9677 | 14.9231 | 3.30304 |
Total Equity | 123.008 | 129.883 | 137.243 | 151.008 | 162.194 |
Common Stock | 0.05919 | 0.0588 | 0.05879 | 0.05856 | 0.05856 |
Additional Paid-In Capital | 512.455 | 511.144 | 509.517 | 507.77 | 506.235 |
Retained Earnings (Accumulated Deficit) | -389.506 | -381.319 | -372.332 | -356.717 | -343.814 |
Total Liabilities & Shareholders’ Equity | 147.282 | 155.616 | 168.219 | 181.292 | 189.692 |
Total Common Shares Outstanding | 59.1873 | 58.8012 | 58.7916 | 58.5601 | 58.5601 |
Cash | 96.8035 | 111.504 | 125.313 | 135.151 | 106.54 |
Other Equity, Total | 0 | 0 | 0 | -0.10394 | -0.28573 |
Other Liabilities, Total | 0 | 0 | |||
Short Term Investments | 0 | 0 | 0 | 29.8815 | 56.6789 |
Redeemable Preferred Stock | 0 | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -62.0246 | -57.7763 | -37.5537 | -60.8268 | -38.8932 |
Cash From Operating Activities | -56.6372 | -42.5559 | -37.4935 | -44.9842 | -29.8571 |
Cash From Operating Activities | 0.25871 | 0.26418 | 0.05622 | 0.09631 | 0.071 |
Non-Cash Items | 8.57288 | 7.5175 | 9.31286 | 14.3154 | 3.96663 |
Cash Interest Paid | 1.33854 | 1.33708 | 1.38775 | 0.23849 | 0.08896 |
Changes in Working Capital | -3.44414 | 7.43869 | -8.82955 | 2.7409 | 4.99848 |
Cash From Investing Activities | -29.9545 | -0.00781 | 29.0239 | 18.4769 | -23.3356 |
Capital Expenditures | -0.01632 | -0.00781 | 0 | -0.00953 | -0.26297 |
Other Investing Cash Flow Items, Total | -29.9382 | 0 | 29.0239 | 18.4864 | -23.0726 |
Cash From Financing Activities | 1.22009 | 194.496 | 41.902 | 23.5757 | 80.5268 |
Financing Cash Flow Items | 0.09667 | 0.06153 | 0.12697 | 0.07166 | 0 |
Issuance (Retirement) of Stock, Net | 1.12343 | 194.435 | 41.7751 | 9.05407 | 81.9227 |
Net Change in Cash | -85.3716 | 151.933 | 33.4325 | -2.93164 | 27.3341 |
Issuance (Retirement) of Debt, Net | 0 | 14.45 | -1.39583 | ||
Deferred Taxes | 0 | -0.47927 | -1.30997 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -15.6157 | -62.0246 | -49.1225 | -34.5692 | -16.7883 |
Cash From Operating Activities | -9.44382 | -56.6372 | -45.406 | -32.8318 | -12.8732 |
Cash From Operating Activities | 0.06697 | 0.25871 | 0.19206 | 0.12675 | 0.06274 |
Non-Cash Items | 4.26297 | 8.57288 | 5.6897 | 3.3879 | 2.01615 |
Cash Interest Paid | 0.3974 | 1.33854 | 0.98183 | 0.65217 | 0.3225 |
Changes in Working Capital | 1.84192 | -3.44414 | -2.1653 | -1.7772 | 1.8362 |
Cash From Investing Activities | 30 | -29.9545 | -56.9545 | -75.9705 | -58.0318 |
Capital Expenditures | 0 | -0.01632 | -0.01632 | -0.01632 | -0.01632 |
Cash From Financing Activities | 0.05256 | 1.22009 | 1.22009 | 0.02332 | 0.02332 |
Financing Cash Flow Items | 0.05256 | 0.09667 | 0.09667 | 0.02332 | 0.02332 |
Issuance (Retirement) of Stock, Net | 1.12343 | 1.12343 | 0 | 0 | |
Net Change in Cash | 20.6087 | -85.3716 | -101.14 | -108.779 | -70.8817 |
Other Investing Cash Flow Items, Total | 30 | -29.9382 | -56.9382 | -75.9542 | -58.0155 |
Deferred Taxes |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Perceptive Advisors LLC | Private Equity | 14.1428 | 8287087 | -3062998 | 2023-10-18 | MED |
Knoll Capital Management, LLC | Hedge Fund | 6.1368 | 3595916 | 580248 | 2023-10-04 | |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 5.4134 | 3172057 | 672896 | 2023-06-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 5.1913 | 3041866 | 2868585 | 2023-06-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.0676 | 2969388 | 2003542 | 2023-06-30 | LOW |
Brady (Todd C) | Individual Investor | 1.9498 | 1142476 | 199251 | 2023-09-07 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 1.921 | 1125645 | 2737 | 2023-06-30 | LOW |
Eagle Asset Management, Inc. | Investment Advisor/Hedge Fund | 1.8065 | 1058546 | -785464 | 2023-06-30 | LOW |
Laurion Capital Management LP | Hedge Fund | 1.709 | 1001377 | 44477 | 2023-06-30 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.6268 | 953250 | 464905 | 2023-06-30 | LOW |
Verition Fund Management LLC | Hedge Fund | 1.5873 | 930074 | -634954 | 2023-06-30 | HIGH |
Fidelity Management & Research Company LLC | Investment Advisor | 1.1626 | 681258 | -107531 | 2023-06-30 | LOW |
Two Sigma Investments, LP | Hedge Fund | 0.9647 | 565300 | -183100 | 2023-06-30 | HIGH |
Millennium Management LLC | Hedge Fund | 0.8458 | 495575 | -622856 | 2023-06-30 | HIGH |
Invesco Capital Management LLC | Investment Advisor | 0.8377 | 490845 | 208139 | 2023-06-30 | LOW |
Johnson & Johnson Innovation-JJDC, Inc. | Venture Capital | 0.6738 | 394834 | 0 | 2023-06-30 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.6334 | 371130 | 286468 | 2023-06-30 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.5211 | 305356 | 57956 | 2023-06-30 | HIGH |
Wells Fargo Advisors | Research Firm | 0.4741 | 277776 | 6261 | 2023-06-30 | LOW |
DWS Investment GmbH | Investment Advisor/Hedge Fund | 0.4558 | 267064 | 43010 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Aldeyra Therapeutics, Inc. Company profile
About Aldeyra Therapeutics Inc
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in developing immune-modulating therapies to treat ocular and systemic diseases. The Company's lead product candidate, reproxalap, is a treatment in late-stage development for dry eye disease (DED) and allergic conjunctivitis (AC). It has additional product candidates in development for proliferative vitreoretinopathy (PVR), primary vitreoretinal lymphoma (PVRL) and other retinal diseases, autoimmune disease, and cancer. The Company's product development pipeline is focused on immune-mediated ocular diseases and select systemic diseases and encompasses three biological mechanisms of action: reactive aldehyde species (RASP) inhibition, dihydrofolate reductase (DHFR) inhibition, and protein chaperome (CHP) inhibition. The immunological activity of its product candidates generally leads to diminished levels of pathological inflammation via down-regulation of immune cell activation or proliferation.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Aldeyra Therapeutics Inc revenues was not reported. Net loss increased 54% to $57.8M. Higher net loss reflects Research and development increase of 98% to $41.4M (expense), General and administrative increase of 15% to $7.7M (expense), General and administrative expenses increase of 8% to $3.5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.11 to -$1.07.
Industry: | Bio Therapeutic Drugs |
131 Hartwell Avenue
Suite 320
LEXINGTON
MASSACHUSETTS 02421
US
Income Statement
- Annual
- Quarterly
News

December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com